TMC3 inhibitors are a class of chemical compounds that specifically target and modulate the activity of the TMC3 protein, a member of the transmembrane channel-like family involved in ion transport and other cellular processes. These inhibitors function by binding to critical regions of the TMC3 protein, often focusing on the active site or key functional domains responsible for regulating the passage of ions across the membrane. By occupying these binding sites, TMC3 inhibitors block the normal flow of ions, preventing the protein from performing its role in cellular signaling and homeostasis. In some cases, these inhibitors may also work by binding to allosteric sites, which are regions on the protein distant from the active site. When bound to these sites, TMC3 inhibitors induce conformational changes that reduce or eliminate the protein's activity. The stability of the inhibitor-protein complex is maintained through non-covalent interactions, including hydrogen bonding, hydrophobic interactions, van der Waals forces, and ionic interactions, ensuring that the inhibitors remain effectively bound to the protein.
The structural diversity of TMC3 inhibitors is crucial to their ability to interact selectively and effectively with the TMC3 protein. These inhibitors often incorporate functional groups such as hydroxyl, amine, or carboxyl groups, which form hydrogen bonds and ionic interactions with the protein's amino acid residues in the active or allosteric sites. Additionally, many TMC3 inhibitors include aromatic rings or heterocyclic structures, which enhance hydrophobic interactions with non-polar regions of the protein, stabilizing the overall binding affinity. The physicochemical properties of TMC3 inhibitors, such as molecular weight, solubility, lipophilicity, and polarity, are carefully optimized to ensure they can bind effectively and remain stable across various biological environments. By balancing hydrophilic and hydrophobic regions, TMC3 inhibitors achieve selective binding to both polar and non-polar regions of the protein, enabling robust and efficient inhibition of TMC3 activity in diverse cellular contexts.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $153.00 | 5 | |
Ibrutinib inhibits Bruton's tyrosine kinase (BTK), a key kinase in B-cell receptor signaling, by covalently binding to its active site cysteine. This disrupts B-cell signaling, inhibiting B-cell proliferation and survival. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib is an epidermal growth factor receptor (EGFR) inhibitor, blocking EGFR tyrosine kinase activity. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Imatinib targets the BCR-ABL fusion protein, which drives chronic myeloid leukemia (CML) and some other cancers. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib is a multi-kinase inhibitor that targets Raf kinases, VEGFR, and PDGFR, blocking angiogenesis and tumor cell proliferation. | ||||||
ABT-199 | 1257044-40-8 | sc-472284 sc-472284A sc-472284B sc-472284C sc-472284D | 1 mg 5 mg 10 mg 100 mg 3 g | $116.00 $330.00 $510.00 $816.00 $1632.00 | 10 | |
ABT-199 (Venetoclax) inhibits B-cell lymphoma-2 (BCL-2), preventing its anti-apoptotic function. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib targets multiple kinases, including BCR-ABL and Src family kinases. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $150.00 $920.00 | 5 | |
Sunitinib inhibits multiple receptor tyrosine kinases, including VEGFR and PDGFR, interfering with angiogenesis and tumor cell growth. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $412.00 | 32 | |
Lapatinib is a dual inhibitor of EGFR and HER2 kinases, hindering the growth of breast cancer cells driven by these receptors. | ||||||
Nilotinib | 641571-10-0 | sc-202245 sc-202245A | 10 mg 25 mg | $205.00 $405.00 | 9 | |
Nilotinib, like imatinib, inhibits BCR-ABL kinase activity. | ||||||
Osimertinib | 1421373-65-0 | sc-507355 | 5 mg | $86.00 | ||
Osimertinib is a selective EGFR inhibitor, particularly effective against T790M mutant EGFR, a common resistance mechanism in non-small cell lung cancer. | ||||||